What's Happening?
Paz Vellanki, MD, PhD, a former Associate Director at the FDA, has joined Precision for Medicine as Vice President of Clinical Development, Oncology. Vellanki brings extensive experience in drug development and regulatory strategy, having worked on FDA guidance
for circulating tumor DNA and served as a liaison to the American Association for Cancer Research. Her role at Precision for Medicine will involve partnering with life sciences companies on clinical development strategy and regulatory planning, enhancing the company's expertise in oncology and biomarker-driven research.
Why It's Important?
Vellanki's appointment strengthens Precision for Medicine's regulatory expertise, providing clients with valuable insights into navigating complex drug development processes. Her experience at the FDA, particularly in oncology, positions the company to better support life sciences firms in bringing precision therapies to market. This move reflects the growing importance of regulatory knowledge in the rapidly evolving field of precision medicine, where timely and effective drug development can significantly impact patient outcomes and healthcare innovation.
